Christoph Nowak
Director Técnico/Científico/I+D en DIAMYD MEDICAL AB .
Fortuna: 581 $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Anders Essen-Möller | M | 83 | 28 años | |
Markus Jerling | M | 72 | 3 años | |
Ulf Hannelius | M | 49 | 8 años | |
Erik Kjellsson Nerpin | M | 63 | 12 años | |
Daniel Ehrenstråhle | M | 50 | 1 años | |
Mark Atkinson | M | 63 | 6 años | |
Martina Widman | F | 43 | 8 años | |
Niclas Holmgren | M | 32 | 1 años | |
Karin Hehenberger | M | 52 | 3 años | |
Carl Torbjörn Bäckström | M | 76 | 7 años | |
Michael Owens | M | 68 | 1 años | |
Anna Styrud | F | 63 | 14 años | |
Theresa Comiskey Olsen | F | 61 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Maria-Teresa Essen-Möller | F | 54 | 15 años | |
Anton Lindqvist | M | 44 | 11 años | |
Karin Rosen | M | 57 | 1 años | |
Eva Karlström | F | 60 | 4 años | |
Stian Kildal | M | - | 1 años | |
Kristofer Svensson | M | - |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | 2 años |
Lars Christer Fedrik Fåhraeus | M | 59 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Paul de Potocki | M | 62 | 2 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 21 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Christoph Nowak
- Red Personal